Immunohistochemical analysis of the novel marginal zone B-cell marker IRTA1 in malignant lymphoma

详细信息    查看全文

• 作者：Jun-ichiro Ikeda ; MD ; PhD ; Masaharu Kohara ; Yoko Tsuruta ; Satoshi Nojima ; MD ; PhD ; Shinichiro Tahara ; MD ; Kenji Ohshima ; MD ; Masako Kurashige ; MD ; Naoki Wada ; MD ; PhD ; Eiichi Morii ; MD ; PhD ; ^{morii@molpath.med.osaka-u.ac.jp}
• 关键词：IRTA1 ; Marginal zone B cell ; Malignant lymphoma ; MALT lymphoma ; Immunohistochemistry
• 刊名：Human Pathology
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：59
• 期：Complete
• 页码：70-79
• 全文大小：4545 K
• 卷排序：59

文摘

Marginal zone lymphoma (MZL) is a low-grade B-cell lymphoma derived from marginal zone B cells. Because of a lack of specific immunohistochemical markers, MZL is mainly diagnosed based on the cytological appearance and growth pattern of the tumor. Marginal zone B cells were recently shown to selectively express immunoglobulin superfamily receptor translocation-associated 1 (IRTA1), but the antibody used in that study is not commercially available. We therefore investigated the IRTA1 expression in nonneoplastic lymphoid tissues and 261 malignant lymphomas, examining the ability of a commercially available antibody to accurately diagnose MZL. Among 37 MZLs, 23 of 25 extranodal MZLs of mucosa-associated lymphoid tissue (MALT lymphomas), 3 of 6 splenic MZLs and 3 of 6 nodal MZLs were positive for IRTA1. Among the 98 diffuse large B-cell lymphomas, 33 were positive for IRTA1, including 1 of 38 follicular lymphomas, and all precursor B-lymphoblastic (2/2) and T-lymphoblastic (7/7) leukemia/lymphomas. Other mature B-cell and T-cell lymphomas, and Hodgkin lymphoma were negative for IRTA1. In MALT lymphoma, positive cells were detected mainly in intraepithelial and subepithelial marginal zone B cells. In 1 case of grade 3 follicular lymphoma, IRTA1 was also expressed in the area of large cell transformation. When tumors were classified as germinal center B cell–like (GCB) or non-GCB using the algorithm of Hans, positive expression of IRTA1 was correlated significantly with non-GCB diffuse large B-cell lymphomas (P < .05). These results demonstrated the ability of the commercially available IRTA1 antibody to distinguish MALT lymphoma from other low-grade B-cell lymphomas.